Want to see MTNB full AI Analyst Report?
Total Valuation
Matinas BioPharma has a market cap or net worth of $4.06M. The enterprise value is $2.68M.
Market Cap$4.06M
Enterprise Value$2.68M
Share Statistics
Matinas BioPharma has 6,406,191 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,406,191
Owned by Insiders―
Owned by Institutions0.71%
Financial Efficiency
Matinas BioPharma’s return on equity (ROE) is -2.14 and return on invested capital (ROIC) is -108.06%.
Return on Equity (ROE)-2.14
Return on Assets (ROA)-1.44
Return on Invested Capital (ROIC)-108.06%
Return on Capital Employed (ROCE)-1.21
Revenue Per Employee0.00
Profits Per Employee-3.45M
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Matinas BioPharma is ―. Matinas BioPharma’s PEG ratio is 0.00490.
PE Ratio―
PS Ratio0.00
PB Ratio0.66
Price to Fair Value0.66
Price to FCF-0.46
Price to Operating Cash Flow-0.63
PEG Ratio0.00490
Income Statement
In the last 12 months, Matinas BioPharma had revenue of 0.00 and earned -10.35M in profits. Earnings per share was -2.00.
Revenue0.00
Gross Profit-456.00K
Operating Income-6.96M
Pretax Income-10.35M
Net Income-10.35M
EBITDA-9.89M
Earnings Per Share (EPS)-2.00
Cash Flow
In the last 12 months, operating cash flow was -6.61M and capital expenditures 0.00, giving a free cash flow of -6.61M billion.
Operating Cash Flow-6.61M
Free Cash Flow-6.61M
Free Cash Flow per Share-1.03
Dividends & Yields
Matinas BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.67
52-Week Price Change-31.20%
50-Day Moving Average0.68
200-Day Moving Average0.88
Relative Strength Index (RSI)43.02
Average Volume (3m)52.28K
Important Dates
Matinas BioPharma upcoming earnings date is May 7, 2026, TBA (Confirmed).
Last Earnings DateAug 19, 2025
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Matinas BioPharma as a current ratio of 2.79, with Debt / Equity ratio of 39.34%
Current Ratio2.79
Quick Ratio2.79
Debt to Market Cap0.22
Net Debt to EBITDA0.27
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Matinas BioPharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Matinas BioPharma EV to EBITDA ratio is -0.06, with an EV/FCF ratio of -0.08.
EV to Sales0.00
EV to EBITDA-0.06
EV to Free Cash Flow-0.08
EV to Operating Cash Flow-0.08
Balance Sheet
Matinas BioPharma has $2.45M in cash and marketable securities with $1.19M in debt, giving a net cash position of $1.26M billion.
Cash & Marketable Securities$2.45M
Total Debt$1.19M
Net Cash$1.26M
Net Cash Per Share$0.20
Tangible Book Value Per Share$0.47
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Matinas BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast49.11%